Parenteral Drug Association
  

Add 2009 PDA/FDA Joint Regulatory Conference headlines to your news reader:

Click to view RSS Feed

Or, paste the URL in the box below into your preferred RSS reader.



Web banner

2009 PDA/FDA Joint Regulatory Conference

AgendaRegister Now
Securing the Future of Medical Product Quality: A 2020 Vision
September 14-18, 2009 | Washington, D.C.

Overview

The PDA/FDA Joint Regulatory Conference offers the unique opportunity for you to join FDA representatives and industry experts in face-to-face dialogues. Each year, FDA speakers provide updates on the current state of efforts impacting the development of global regulatory strategies; while industry professionals from some of today’s leading pharmaceutical companies present case studies on how they employ global strategies in their daily processes.

Hear directly from FDA experts and representatives of global regulatory authorities, and take home best practices for compliance. You won’t find this level of direct information exchange with FDA at any other conference!

PDA is also offering an exhibition during the conference, September 14-15. The PDA Training and Research Institute (PDA TRI) will host courses immediately following the conference, September 17-18, to complement what you learn at the meeting.

Contact

Conference inquiries:
Wanda Neal,  Vice President, Programs and Registration Services
Tel: +1 (301) 656-5900 ext. 111
Email: neal@pda.org

Leslie Edmonds, Assistant Manager, Programs
Tel: +1 (301) 656-5900 ext. 160
Email: edmonds@pda.org


Registration inquiries:
Patresa Day, Assistant Manager of Registration and Customer Service
Tel: +1 (301) 656-5900 ext. 115
Email: day@pda.org


PDA TRI course inquiries:

Stephanie Ko, Manager, Lecture Education
Tel: +1 (301) 656-5900 ext. 151
Email: ko@pda.org

 

Exhibition/Sponsorship inquiries:
Nahid Kiani,Vice President, Membership Services and Sales
Tel: +1 (301) 656-5900 ext. 128
Email: kiani@pda.org


For more information about obtaining a U.S. visa, visit http://www.unitedstatesvisas.gov/.

Resources Section

  • PDFMichael Bonney
    Michael W. Bonney, President and CEO, Cubist Pharmaceuticals, Inc.

  • PDFJoseph C. Famulare
    Joseph C. Famulare, Deputy Director, Office of Compliance, Center for Drug Evaluation and Research, FDA

  • PDFThomas Friedli, PhD
    Thomas Friedli, Managing Director Tectem, University of St. Gallen, Switzerland

  • PDFRick Friedman
    Rick Friedman, Director, Division of Manufacturing and Product Quality, CDER, FDA

  • PDFNigel Hamilton
    Nigel Hamilton, Quality Director, Sanofi Aventis

  • PDFBrian Hasselbalch
    Brian Hasselbalch,Team Leader, Guidance and Policy Team, FDA/CDER/Office of Compliance

  • PDFDaniel G. McChesney, M.S., PhD
    Daniel G. McChesney, M.S., PhD Director, Office of Surveillance & Compliance Center for Veterinary Medicine, FDA

  • PDFUlku Oktem, PhD
    Ulku Oktem, PhD, Adjunct Professor, Operations and Information Management Department, Wharton School of the University of Pennsylvania

  • PDFAnurag Rathore, PhD
    Anurag Rathore, PhD, Process Development, Amgen, Inc.

  • PDFStephan Ronninger
    Stephan Roenninger, Global Quality Manager, F. Hoffmann-La Roche, Ltd.

  • PDFBarbara Ryan
    Barbara Ryan, Analyst, Deutsche Bank

  • PDFSwroop Sahota, PhD
    Swroop Sahota, PhD Vice-president of Global Quality Services, Schering-Plough

  • PDFJacqueline Scott
    Jacqueline Scott, Professor, Harrison Institute for Public Law, Georgetown University

  • PDFJoshua M. Sharfstein, MD
    Joshua M. Sharfstein, MD, Principal Deputy Commissioner, FDA

  • PDFJames Skrine
    James Skrine, Executive Director / Site Head, Quality, Amgen, Inc.

  • PDFWayne Taylor, PhD
    Wayne Taylor, PhD, Chairman, Taylor Enterprises

  • PDFWallace Torres
    Wallace Torres, QuaSaR Program Leader, Hoffman-La Roche Inc.

 
From: 
Email:  
To: 
Email:  
Subject: 
Message: